Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis.

Ito Y, Ambe K, Hayase T, Kobayashi M, Tohkin M.

Clin Transl Sci. 2019 Dec 27. doi: 10.1111/cts.12732. [Epub ahead of print]

PMID:
31880866
2.

Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.

Sanagawa A, Hotta Y, Kondo M, Nishikawa R, Tohkin M, Kimura K.

Anticancer Drugs. 2020 Feb;31(2):183-189. doi: 10.1097/CAD.0000000000000862.

PMID:
31789626
3.

Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system.

Goto T, Tohkin M, Yamazoe Y.

Drug Metab Pharmacokinet. 2019 Dec;34(6):351-364. doi: 10.1016/j.dmpk.2019.05.003. Epub 2019 May 31.

PMID:
31563329
4.

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.

Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S.

Cancer Sci. 2019 Oct;110(10):3267-3274. doi: 10.1111/cas.14178. Epub 2019 Sep 19.

5.

Comparison of the developmental/reproductive toxicity and hepatotoxicity of phthalate esters in rats using an open toxicity data source.

Ambe K, Sakakibara Y, Sakabe A, Makino H, Ochibe T, Tohkin M.

J Toxicol Sci. 2019;44(4):245-255. doi: 10.2131/jts.44.245.

6.

Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: Solving the modes of the metabolism and inhibition.

Yamazoe Y, Goto T, Tohkin M.

Drug Metab Pharmacokinet. 2019 Apr;34(2):113-125. doi: 10.1016/j.dmpk.2018.10.001. Epub 2018 Oct 15.

PMID:
30639283
7.

Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer.

Ikeda M, Ochibe T, Tohkin M.

Ther Innov Regul Sci. 2019 May;53(3):324-331. doi: 10.1177/2168479018791135. Epub 2018 Aug 8.

PMID:
30089401
8.

Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.

Sakaeda T, Kobuchi S, Yoshioka R, Haruna M, Takahata N, Ito Y, Sugano A, Fukuzawa K, Hayase T, Hayakawa T, Nakayama H, Takaoka Y, Tohkin M.

Int J Med Sci. 2018 Jun 13;15(9):937-943. doi: 10.7150/ijms.22224. eCollection 2018.

9.

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.

Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K.

Cancer Med. 2018 Jun;7(6):2269-2279. doi: 10.1002/cam4.1429. Epub 2018 Apr 16.

10.

In Silico Prediction of Chemical-Induced Hepatocellular Hypertrophy Using Molecular Descriptors.

Ambe K, Ishihara K, Ochibe T, Ohya K, Tamura S, Inoue K, Yoshida M, Tohkin M.

Toxicol Sci. 2018 Apr 1;162(2):667-675. doi: 10.1093/toxsci/kfx287.

PMID:
29309657
11.

Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

Kaneko M, Aoyama T, Ishida Y, Miyamoto A, Saito Y, Tohkin M, Kawai S, Matsumoto Y.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):199-214. doi: 10.1007/s10928-017-9556-7. Epub 2017 Nov 23.

PMID:
29170990
12.

Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan.

Asano K, Uyama Y, Tohkin M.

Clin Transl Sci. 2018 Mar;11(2):182-188. doi: 10.1111/cts.12520. Epub 2017 Nov 15.

13.

Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.

Aoyama T, Ishida Y, Kaneko M, Miyamoto A, Saito Y, Tohkin M, Kawai S, Matsumoto Y.

CPT Pharmacometrics Syst Pharmacol. 2017 Dec;6(12):823-832. doi: 10.1002/psp4.12259. Epub 2017 Nov 23.

14.
15.

The Survey of the Compliance Situation to the Antihypertensive Therapy Guideline by Analyzing Japanese National Claims Data.

Hagiwara H, Nishikawa R, Fukuzawa K, Tohkin M.

Yakugaku Zasshi. 2017;137(7):893-901. doi: 10.1248/yakushi.17-00038.

16.

Current Status of Regulatory Science Education in Faculties of Pharmaceutical Science in Japan.

Tohkin M.

Yakugaku Zasshi. 2017;137(4):453-457. doi: 10.1248/yakushi.16-00244-7. Review. Japanese.

17.

Ethnic Difference in the Pharmacodynamics-efficacy Relationship of Dipeptidyl Peptidase-4 Inhibitors Between Japanese and non-Japanese Patients: A Systematic Review.

Ito Y, Ambe K, Kobayashi M, Tohkin M.

Clin Pharmacol Ther. 2017 Oct;102(4):701-708. doi: 10.1002/cpt.692. Epub 2017 May 27. Review.

PMID:
28378919
18.

Cross-Classification of Human Urinary Lipidome by Sex, Age, and Body Mass Index.

Okemoto K, Maekawa K, Tajima Y, Tohkin M, Saito Y.

PLoS One. 2016 Dec 14;11(12):e0168188. doi: 10.1371/journal.pone.0168188. eCollection 2016.

19.

Regulatory science plays an important role in the global development of new drugs.

Tohkin M.

Nihon Yakurigaku Zasshi. 2016 Jul;148(1):18-21. doi: 10.1254/fpj.148.18. Japanese. No abstract available.

PMID:
27430674
20.

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S.

Br J Clin Pharmacol. 2016 Jun;81(6):1078-90. doi: 10.1111/bcp.12884. Epub 2016 Mar 14.

21.

[Regulatory science for the proper evaluation of biomarkers (overview)].

Tohkin M, Saito Y.

Yakugaku Zasshi. 2015;135(5):649-53. doi: 10.1248/yakushi.14-00230-1. Review. Japanese.

22.

[Regulatory science on biomarker usage for development and proper use of drugs].

Saito Y, Tohkin M.

Yakugaku Zasshi. 2015;135(5):647-8. doi: 10.1248/yakushi.14-00230-F. Japanese. No abstract available.

23.

[Basic principles of interpretation of hepatocellular hypertrophy in risk assessment in Japan].

Yoshida M, Umemura T, Kojima H, Inoue K, Takahashi M, Uramaru N, Kitamura S, Abe K, Tohkin M, Ozawa S, Yoshinari K.

Shokuhin Eiseigaku Zasshi. 2015;56(2):42-8. doi: 10.3358/shokueishi.56.42. Review. Japanese.

24.

Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients.

Hanatani T, Sai K, Tohkin M, Segawa K, Saito Y.

Int J Clin Pharm. 2015 Jun;37(3):537-45. doi: 10.1007/s11096-015-0097-0. Epub 2015 Mar 31.

PMID:
25822043
25.

The effectiveness of risk communication regarding drug safety information: a nationwide survey by the Japanese public health insurance claims data.

Hagiwara H, Nakano S, Ogawa Y, Tohkin M.

J Clin Pharm Ther. 2015 Jun;40(3):273-8. doi: 10.1111/jcpt.12256. Epub 2015 Mar 6.

PMID:
25753581
26.

No contribution of the ABCB11 p.444A polymorphism in Japanese patients with drug-induced cholestasis.

Kagawa T, Hirose S, Arase Y, Oka A, Anzai K, Tsuruya K, Shiraishi K, Orii R, Ieda S, Nakazawa T, Tomita K, Hokari R, Miura S, Ebinuma H, Saito H, Kitamura T, Horie Y, Okuse C, Wasada M, Inoko H, Tohkin M, Saito Y, Maekawa K, Takikawa H, Mine T.

Drug Metab Dispos. 2015 May;43(5):691-7. doi: 10.1124/dmd.114.061325. Epub 2015 Feb 23.

PMID:
25713208
27.

Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel.

Hanatani T, Sai K, Tohkin M, Segawa K, Antoku Y, Nakashima N, Yokoi H, Ohe K, Kimura M, Hori K, Kawakami J, Saito Y.

J Clin Pharm Ther. 2014 Aug;39(4):361-7. doi: 10.1111/jcpt.12153. Epub 2014 Mar 24.

PMID:
24661251
28.
29.

Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects.

Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, Furuya H, Ikeda H, Takahashi Y, Muramatsu M, Tohkin M, Ozeki T, Mushiroda T, Kubo M, Kamatani N, Abe M, Yagami A, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Matsunaga K, Aihara M; Japan Pharmacogenomics Data Science Consortium.

Pharmacogenomics. 2013 Nov;14(15):1821-31. doi: 10.2217/pgs.13.180.

PMID:
24236482
30.

The aryl hydrocarbon receptor and glucocorticoid receptor interact to activate human metallothionein 2A.

Sato S, Shirakawa H, Tomita S, Tohkin M, Gonzalez FJ, Komai M.

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):90-9. doi: 10.1016/j.taap.2013.08.017. Epub 2013 Aug 28.

31.

An algorithm for the identification of heparin-induced thrombocytopenia using a medical information database.

Hanatani T, Sai K, Tohkin M, Segawa K, Kimura M, Hori K, Kawakami J, Saito Y.

J Clin Pharm Ther. 2013 Oct;38(5):423-8. doi: 10.1111/jcpt.12083. Epub 2013 Jul 12.

PMID:
23845189
32.

Development of a detection algorithm for statin-induced myopathy using electronic medical records.

Sai K, Hanatani T, Azuma Y, Segawa K, Tohkin M, Omatsu H, Makimoto H, Hirai M, Saito Y.

J Clin Pharm Ther. 2013 Jun;38(3):230-5. doi: 10.1111/jcpt.12063. Epub 2013 Mar 26.

PMID:
23530940
33.

Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.

Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H.

Biol Pharm Bull. 2012;35(5):717-24.

34.
35.

A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z; Japan Pharmacogenomics Data Science Consortium.

Pharmacogenomics J. 2013 Feb;13(1):60-9. doi: 10.1038/tpj.2011.41. Epub 2011 Sep 13.

PMID:
21912425
36.

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.

Epilepsia. 2010 Dec;51(12):2461-5. doi: 10.1111/j.1528-1167.2010.02766.x. Epub 2010 Nov 3.

37.

Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene.

Saeki M, Kurose K, Hasegawa R, Tohkin M.

Mol Genet Metab. 2011 Jan;102(1):91-8. doi: 10.1016/j.ymgme.2010.08.019. Epub 2010 Sep 19.

PMID:
20855224
38.

CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.

Maekawa K, Harakawa N, Yoshimura T, Kim SR, Fujimura Y, Aohara F, Sai K, Katori N, Tohkin M, Naito M, Hasegawa R, Okuda H, Sawada J, Niwa T, Saito Y.

Drug Metab Dispos. 2010 Dec;38(12):2100-4. doi: 10.1124/dmd.110.034140. Epub 2010 Sep 16.

PMID:
20847137
39.

Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.

Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R.

Drug Metab Pharmacokinet. 2010;25(2):122-33.

40.

Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.

Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG.

Drug Metab Pharmacokinet. 2009;24(6):553-6.

41.

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.

Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J.

Drug Metab Dispos. 2009 Sep;37(9):1895-903. doi: 10.1124/dmd.109.027003. Epub 2009 Jun 18.

PMID:
19541829
42.

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.

Pharmacogenomics. 2008 Nov;9(11):1617-22. doi: 10.2217/14622416.9.11.1617.

PMID:
19018717
43.

Identification of the functional vitamin D response elements in the human MDR1 gene.

Saeki M, Kurose K, Tohkin M, Hasegawa R.

Biochem Pharmacol. 2008 Aug 15;76(4):531-42. doi: 10.1016/j.bcp.2008.05.030. Epub 2008 Jul 2.

PMID:
18602086
44.

Thyroid hormone receptor mediates human MDR1 gene expression-Identification of the response region essential for gene expression.

Kurose K, Saeki M, Tohkin M, Hasegawa R.

Arch Biochem Biophys. 2008 Jun 1;474(1):82-90. doi: 10.1016/j.abb.2008.03.020. Epub 2008 Mar 25.

PMID:
18395509
45.

Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver.

Sato S, Shirakawa H, Tomita S, Ohsaki Y, Haketa K, Tooi O, Santo N, Tohkin M, Furukawa Y, Gonzalez FJ, Komai M.

Toxicol Appl Pharmacol. 2008 May 15;229(1):10-9. doi: 10.1016/j.taap.2007.12.029. Epub 2008 Jan 17.

PMID:
18295293
46.

Genetic variations of the ABC transporter gene ABCC3 in a Japanese population.

Fukushima-Uesaka H, Saito Y, Maekawa K, Hasegawa R, Suzuki K, Yanagawa T, Kajio H, Kuzuya N, Noda M, Yasuda K, Tohkin M, Sawada J.

Drug Metab Pharmacokinet. 2007 Apr;22(2):129-35.

47.

Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population.

Fukushima-Uesaka H, Saito Y, Tohkin M, Maekawa K, Hasegawa R, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Kajio H, Kuzuya N, Yasuda K, Sawada J.

Drug Metab Pharmacokinet. 2007 Feb 25;22(1):48-60.

48.

Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.

Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J.

Pharmacogenet Genomics. 2006 Jul;16(7):497-514.

PMID:
16788382
49.

Identification of regulatory sites in the human PXR (NR1I2) promoter region.

Kurose K, Ikeda S, Koyano S, Tohkin M, Hasegawa R, Sawada J.

Mol Cell Biochem. 2006 Jan;281(1-2):35-43.

PMID:
16328955
50.

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.

Diabetes Res Clin Pract. 2006 May;72(2):148-54. Epub 2005 Dec 1.

PMID:
16325295

Supplemental Content

Loading ...
Support Center